For the past years, we’ve been developing a robust pipeline for identification of neoantigens. These are immunogenic proteins present on the surface of the tumour cells but absent on the healthy control cells. Neoantigens are then targeted during subsequent immunotherapy.
Only certain patients are going to be treated with immunotherapy. Patients for which immune programs are too advanced/unfeasible will be pushed to take a different treatment direction. Feasibility predictions are made based on the clinical results of the therapy correlated with the genomic data of the patient.
Since we are performing a Whole Exome + Transcriptome Sequencing of the patient’s normal/tumour genome, we can use the data for purposes not (directly) related to Immunology as well. These include the MHC (sub) typing, the Tumor Mutational Burden, the tumor type/subtyping, the CTA gene expression, etc.